The North America point-of-care molecular testing for infectious diseases market size is projected to reach US$ 2.62 billion by 2031 from US$ 1.09 billion in 2023. The market is expected to register a CAGR of 11.5% during 2023–2031. The rising number of product approvals and launches are likely to remain a key trend in the market.
North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis
The surging prevalence of infectious diseases and the preference for rapid diagnostic solutions are the key factors driving the market development. Furthermore, the rising focus on R&D and funding in infectious disease diagnostics is expected to create lucrative opportunities for the growth of the North American point-of-care testing in the infectious disease market in the coming years. For instance, in January 2023, 19 to Zero, a nonprofit behavioral sciences initiative group, received financing from BD through an educational grant for a point-of-care testing pilot in the primary care environment. A financial award was accompanied by the provision of multiple BD Veritor Plus System Analyzers and BD Veritor System for Rapid Detection Assays to facilitate point-of-care diagnostic testing for influenza A and B, RSV, SARS-CoV-2, Group A strep, and triplex.
North America Point-of-Care Molecular Testing for Infectious Diseases Market Overview
Infectious diseases adversely affect public health, causing morbidity, mortality, and economic burdens. The effective management, treatment, and prevention of these health conditions require accurate and timely diagnosis. Molecular diagnostics techniques, laboratory-based assays, and point-of-care tests are employed for the diagnosis of HIV, tuberculosis, and hepatitis C; human papillomavirus screening for cervical cancer; and the monitoring of health and treatment progress in patients. Healthcare providers turn to point-of-care testing to streamline diagnostic processes, reduce turnaround times, and enhance patient care. These tests also ease diagnoses during infectious disease outbreaks. According to data published by the CDC in 2022, Florida (US) suffered the onset of concurrent epidemics of hepatitis A, invasive meningococcal disease (IMD), and mpox (formerly known as monkeypox). Mpox cases were more strongly concentrated in South Florida and peaked in August. In contrast, the hepatitis A and IMD epidemics were centered in Central Florida and peaked from March to June. Nearly 2,845 cases of mumps were reported in Florida as part of a worldwide outbreak. HIV infection was found in 52% of mpox patients compared to 21% of hepatitis A and 34% of IMD cases. These pathogens include hepatitis A, mpox, and meningococcal disease. The need for quick identification and containment of infectious pathogens propelled the demand for innovative point-of-care testing solutions in North America.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
North America Point-of-Care Molecular Testing for Infectious Diseases Market: Strategic Insights
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
North America Point-of-Care Molecular Testing for Infectious Diseases Market: Strategic Insights
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
North America Point-of-Care Molecular Testing for Infectious Diseases Market Drivers and Opportunities
Preference for Rapid Diagnostic Solutions Favors Market Growth
Healthcare providers emphasize on the quick and accurate diagnosis of infectious diseases such as HIV infections, hepatitis, and influenza. POC testing aids in the rapid identification of specific viruses and bacteria, enabling timely treatment decisions and improved patient outcomes. The time taken by POC tests to deliver results may vary from minutes to hours, whereas traditional laboratory testing may take days to produce results. Simple test kits detect proteins released by pathogens or those present on cell surfaces, among others, from samples; they can also detect human antibodies produced in response to infection from blood or serum. The rapid turnaround time enables the prompt initiation of appropriate treatments and helps prevent the spread of infectious diseases within communities. Advancements in POC testing technologies have further enhanced these diagnostic devices with greater accuracy, sensitivity, and ease of use, making them more reliable and user-friendly for healthcare professionals. These technological innovations have expanded the capabilities of POC testing for infectious diseases, allowing for the detection of a wider range of pathogens with greater precision. Additionally, the increasing inclination toward personalized medicine in healthcare has propelled the demand for POC testing products. By providing real-time diagnostic information at the point of care, POC testing enables healthcare providers to tailor treatment plans based on each patient's infection profile, leading to more effective and personalized care.
Increasing Focus on R&D and Funding in Infectious Disease Diagnostics
Research and development (R&D) is an essential component for pharmaceutical and biopharmaceutical companies. R&D enables market players to develop new products for various therapeutic applications with significant medical and commercial potential. The following table displays the annual funding for various research and disease categories based on contracts, grants, and other funding mechanisms adopted by the NIH.
Infectious Diseases and Fundings
Research/Disease Areas | 2019 (US$ Million) | 2020 (US$ Million) | 2021 (US$ Million) | 2022 (US$ Million) |
Emerging Infectious Diseases | 2,950 | 4,867 | 5,069 | 4,318 |
Infectious Diseases | 6,313 | 8,301 | 8,599 | 8,019 |
Sexually Transmitted Infections | 354 | 394 | 404 | 419 |
Note: The current conversion rate is considered for the currencies.
Source: Annual Reports and The Insight Partners Analysis
In response to the shortage of laboratory capabilities and molecular testing reagents, coupled with the rising cases of infectious diseases, diagnostic testing manufacturers offer fast and easy-to-use devices to facilitate out-of-laboratory testing.
North America Point-of-Care Molecular Testing for Infectious Diseases Market Report Segmentation Analysis
Key segments that contributed to the derivation of the North America point-of-care molecular testing for infectious diseases market analysis are disease, technology, prescription testing, sample, distribution channel, and end user.
- Based on disease, the North America point-of-care molecular testing for infectious diseases market is divided into HIV testing, influenza testing, sexually transmitted diseases testing, hepatitis C virus testing, tropical diseases testing, respiratory infection testing, hospital-acquired infections, strep, and others. The market is further divided on the basis of molecular diagnostics into polymerase chain reactions (PCR), isothermal nucleic acid amplification technology (INAAT), and others. The respiratory infection testing segment held the largest market share in 2023.
- By technology, the market is segmented into lateral flow assay, dipsticks, microfluidics, molecular diagnostics, immunoassays, solid phase, and others. The lateral flow assay segment held the largest share of the market in 2023.
- In terms of sample, the market is segmented into blood samples, urine samples, nasal and oropharyngeal swabs, and others. The blood sample segment held the largest market share in 2023.
- In terms of end user, the market is segmented into hospitals and clinics, home care settings, ambulatory and urgent care facilities, nursing homes and assisted living facilities, research laboratories, and diagnostics centers. The market is further divided on the basis of hospitals and clinics into clinical laboratories, professional physician offices, and others. The hospitals and clinics segment held the largest market share in 2023.
North America Point-of-Care Molecular Testing for Infectious Diseases Market Share Analysis by Country
The scope of the North America point-of-care molecular testing for infectious diseases market report is mainly divided into three countries: US, Canada, and Mexico.
The increasing prevalence of infectious diseases, the rising geriatric population, and a surging number of product launches by key players are the primary contributors to the point-of-care testing for infectious diseases market growth in the US. Aging is a prominent risk factor for infectious diseases, as people aged more than 60 may have compromised immunity. According to a study published by the Population Reference Bureau in 2020, the population of individuals aged 65 and above was 55 million in the US in 2020, and the number is expected to reach 95 million by 2060. Regulatory agencies in the US rigorously monitor the development of point-of-care (POC) testing products. For instance, in March 2021, the US Food Drug Administration (FDA) authorized Binx Health IO CT/NG Assay for community-based clinics, urgent care settings, and outpatient healthcare facilities; it is the first POC testing product for diagnosing chlamydial and gonorrheal infections.
North America Point-of-Care Molecular Testing for Infectious Diseases Market Report Scope
North America Point-of-Care Molecular Testing for Infectious Diseases Market News and Recent Developments
The North America point-of-care molecular testing for infectious diseases market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the North America point-of-care molecular testing for infectious diseases market are listed below:
- Roche received FDA approval for the first molecular test to screen for malaria in blood donors in the US. Roche's cobas Malaria test was approved by the FDA for use on the cobas 6800/8800 Systems. The test identifies infected blood units, making the process of blood donation and transfusion safer. The test screens for the five main species of Plasmodium parasites that cause infection in humans. It can be used to screen blood, organ, and tissue donors, thereby improving blood safety and availability. (Source: QuidelOrtho, Company Website, April 2024)
North America Point-of-Care Molecular Testing for Infectious Diseases Market Report Coverage and Deliverables
The “North America Point-of-Care Molecular Testing for Infectious Diseases Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:
- North America point-of-care molecular testing for infectious diseases market size and forecast at regional and country levels for all the key market segments covered under the scope
- North America point-of-care molecular testing for infectious diseases market trends as well as market dynamics such as drivers, restraints, and key opportunities
- Detailed PEST/Porter’s Five Forces and SWOT analysis
- North America point-of-care molecular testing for infectious diseases market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the North America point-of-care molecular testing for infectious diseases market.
- Detailed company profiles
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The rising number of product approvals and launches are likely to be key trends in the market in the future.
Key market players include Abbott Laboratories, Agilent Technologies Inc, Becton Dickinson and Co, Bio-Rad Laboratories Inc, Cardinal Health Inc, Danaher Corp, Cue Health Inc, QuidelOrtho Corp, Thermo Fisher Scientific Inc, and F. Hoffmann-La Roche Ltd.
The surging prevalence of infectious diseases and the preference for rapid diagnostic solutions are the key driving factors behind the market development. Further, the increasing focus on R&D and funding in infectious disease diagnostics are expected to bolster the growth of the market in the coming years.
The North America point-of-care testing for infectious diseases market is segmented into the US, Canada, and Mexico. The US held the largest market share in 2023.
The market is expected to register a CAGR of 11.5% during 2023–2031.
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.3 Hypothesis formulation
3.3.1 Macro-economic factor analysis:
3.3.2 Developing base number:
3.3.3 Data Triangulation:
3.3.4 Country level data:
4. North America Point-of-Care Molecular Testing for Infectious Diseases Market Landscape
4.1 Overview
4.2 PEST Analysis
5. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Key Market Dynamics
5.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Surging Prevalence of Infectious Diseases
5.2.2 Preference for Rapid Diagnostic Solutions
5.3 Market Restraints
5.3.1 Inadequate Reimbursement Scenario
5.4 Market Opportunities
5.4.1 Increasing Focus on R&D and Funding in Infectious Disease Diagnostics
5.5 Future Trends
5.5.1 Rising Number of Product Approvals and Launches
5.6 Impact of Drivers and Restraints:
6. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis
6.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue (US$ Million), 2021–2031
6.2 North America Point-of-Care Molecular Testing for Infectious Diseases Market Forecast and Analysis
6.3 Market Share Analysis, By Companies (2023)
6.4 Pricing Analysis
6.5 Pre and Post COVID-19 Impact
6.6 Intellectual Property Rights of Products/Companies
6.6.1 POC Patent Filing
6.7 Novel Companies Entering the Point of Care Testing Market For Infectious Diseases Application
7. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis – by Diseases
7.1 HIV Testing
7.1.1 Overview
7.1.2 HIV Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Influenza Testing
7.2.1 Overview
7.2.2 Influenza Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Sexually Transmitted Diseases Testing
7.3.1 Overview
7.3.2 Sexually Transmitted Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
7.3.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sexually Transmitted Diseases Testing
7.4 Hepatitis C Virus Testing
7.4.1 Overview
7.4.2 Hepatitis C Virus Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Tropical Diseases Testing
7.5.1 Overview
7.5.2 Tropical Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
7.5.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Tropical Diseases Testing
7.6 Respiratory Infection Testing
7.6.1 Overview
7.6.2 Respiratory Infection Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
7.7 Hospital Acquired Infections
7.7.1 Overview
7.7.2 Hospital Acquired Infections: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
7.8 Strep
7.8.1 Overview
7.8.2 Strep: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
7.9 Others
7.9.1 Overview
7.9.2 Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
8. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis – by Technology
8.1 Lateral Flow Assay
8.1.1 Overview
8.1.2 Lateral Flow Assay: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
8.2 Dipsticks
8.2.1 Overview
8.2.2 Dipsticks: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
8.3 Microfluidics
8.3.1 Overview
8.3.2 Microfluidics: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
8.4 Molecular Diagnostics
8.4.1 Overview
8.4.2 Molecular Diagnostics: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
8.4.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Molecular Diagnostics
8.4.2.1.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Polymerase Chain Reactions (PCR)
8.5 Immunoassays
8.5.1 Overview
8.5.2 Immunoassays: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
8.6 Solid Phase
8.6.1 Overview
8.6.2 Solid Phase: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
8.7 Others
8.7.1 Overview
8.7.2 Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
9. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis – by Prescription Testing
9.1 Prescription Based Testing
9.1.1 Overview
9.1.2 Prescription Based Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
9.2 OTC Testing
9.2.1 Overview
9.2.2 OTC Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
10. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis – by Sample
10.1 Blood Sample
10.1.1 Overview
10.1.2 Blood Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
10.2 Urine Sample
10.2.1 Overview
10.2.2 Urine Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
10.3 Nasal and Oropharyngeal Swabs Sample
10.3.1 Overview
10.3.2 Nasal and Oropharyngeal Swabs Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
10.4 Others
10.4.1 Overview
10.4.2 Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
11. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis – by End User
11.1 Hospitals and Clinics
11.1.1 Overview
11.1.2 Hospitals and Clinics: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
11.1.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Hospitals and Clinics
11.2 Home Care Settings
11.2.1 Overview
11.2.2 Home Care Settings: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
11.3 Ambulatory and Urgent Care Facilities
11.3.1 Overview
11.3.2 Ambulatory and Urgent Care Facilities: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
11.4 Nursing Home and Assisted Living Facilities
11.4.1 Overview
11.4.2 Nursing Home and Assisted Living Facilities: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
11.5 Research Laboratories
11.5.1 Overview
11.5.2 Research Laboratories: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
11.6 Diagnostics Centers
11.6.1 Overview
11.6.2 Diagnostics Centers: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
12. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis – by Distribution Channel
12.1 E-Com Platforms
12.1.1 Overview
12.1.2 E-Com Platforms: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
12.2 Retail Channel and Pharmacies
12.2.1 Overview
12.2.2 Retail Channel and Pharmacies: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
12.3 Others
12.3.1 Overview
12.3.2 Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
13. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Country Analysis
13.1 North America
13.1.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Countries
13.1.2 North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue and Forecast and Analysis – by Country
13.1.2.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue and Forecast and Analysis – by Country
13.1.2.2 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
13.1.2.2.1 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Diseases
13.1.2.2.2 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sexually Transmitted Diseases Testing
13.1.2.2.3 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Tropical Diseases Testing
13.1.2.2.4 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Technology
13.1.2.2.5 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Molecular Diagnostics
13.1.2.2.6 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Polymerase Chain Reactions (PCR)
13.1.2.2.7 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Prescription Testing
13.1.2.2.8 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sample
13.1.2.2.9 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by End User
13.1.2.2.10 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Hospitals And Clinics
13.1.2.2.11 United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Distribution Channel
13.1.2.3 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
13.1.2.3.1 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Diseases
13.1.2.3.2 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sexually Transmitted Diseases Testing
13.1.2.3.3 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Tropical Diseases Testing
13.1.2.3.4 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Technology
13.1.2.3.5 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Molecular Diagnostics
13.1.2.3.6 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Polymerase Chain Reactions (PCR)
13.1.2.3.7 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Prescription Testing
13.1.2.3.8 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sample
13.1.2.3.9 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by End User
13.1.2.3.10 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Hospitals And Clinics
13.1.2.3.11 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Distribution Channel
13.1.2.4 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
13.1.2.4.1 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Diseases
13.1.2.4.2 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sexually Transmitted Diseases Testing
13.1.2.4.3 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Tropical Diseases Testing
13.1.2.4.4 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Technology
13.1.2.4.5 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Molecular Diagnostics
13.1.2.4.6 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Polymerase Chain Reactions (PCR)
13.1.2.4.7 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Prescription Testing
13.1.2.4.8 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Sample
13.1.2.4.9 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by End User
13.1.2.4.10 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Hospitals And Clinics
13.1.2.4.11 Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Distribution Channel
14. North America Point-Of-Care Molecular Testing for Infectious Diseases Market – Industry Landscape
14.1 Overview
14.2 Growth Strategies in North America Point-Of-Care Molecular Testing for Infectious Diseases Market
14.3 Organic Growth Strategies
14.3.1 Overview
14.4 Inorganic Growth Strategies
14.4.1 Overview
15. Company Profiles
15.1 Abbott Laboratories
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 Agilent Technologies Inc
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 Becton Dickinson and Co
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 Bio-Rad Laboratories Inc
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Products and Services
15.4.4 Financial Overview
15.4.5 SWOT Analysis
15.4.6 Key Developments
15.5 Cardinal Health Inc
15.5.1 Key Facts
15.5.2 Business Description
15.5.3 Products and Services
15.5.4 Financial Overview
15.5.5 SWOT Analysis
15.5.6 Key Developments
15.6 Danaher Corp
15.6.1 Key Facts
15.6.2 Business Description
15.6.3 Products and Services
15.6.4 Financial Overview
15.6.5 SWOT Analysis
15.6.6 Key Developments
15.7 Cue Health Inc
15.7.1 Key Facts
15.7.2 Business Description
15.7.3 Products and Services
15.7.4 Financial Overview
15.7.5 SWOT Analysis
15.7.6 Key Developments
15.8 QuidelOrtho Corp
15.8.1 Key Facts
15.8.2 Business Description
15.8.3 Products and Services
15.8.4 Financial Overview
15.8.5 SWOT Analysis
15.8.6 Key Developments
15.9 Thermo Fisher Scientific Inc
15.9.1 Key Facts
15.9.2 Business Description
15.9.3 Products and Services
15.9.4 Financial Overview
15.9.5 SWOT Analysis
15.9.6 Key Developments
15.10 F. Hoffmann-La Roche Ltd
15.10.1 Key Facts
15.10.2 Business Description
15.10.3 Products and Services
15.10.4 Financial Overview
15.10.5 SWOT Analysis
15.10.6 Key Developments
16. Appendix
16.1 About The Insight Partners
16.2 Glossary of Terms
1.1.1 List of Tables
Table 1. North America Point-of-Care Molecular Testing for Infectious Diseases Market Segmentation
Table 2. Infectious Diseases and Fundings
Table 3. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Table 4. Market Share Analysis, By Companies (2023)
Table 5. Pricing Analysis
Table 6. List of Patent filed by Companies
Table 7. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Diseases
Table 8. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sexually Transmitted Diseases Testing
Table 9. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Tropical Diseases Testing
Table 10. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Technology
Table 11. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Molecular Diagnostics
Table 12. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Polymerase Chain Reactions (PCR)
Table 13. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Prescription Testing
Table 14. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sample
Table 15. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 16. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Hospitals and Clinics
Table 17. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Distribution Channel
Table 18. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Country
Table 19. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Diseases
Table 20. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sexually Transmitted Diseases Testing
Table 21. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Tropical Diseases Testing
Table 22. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Technology
Table 23. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Molecular Diagnostics
Table 24. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Polymerase Chain Reactions (PCR)
Table 25. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Prescription Testing
Table 26. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sample
Table 27. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 28. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Hospitals And Clinics
Table 29. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Distribution Channel
Table 30. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Diseases
Table 31. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sexually Transmitted Diseases Testing
Table 32. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Tropical Diseases Testing
Table 33. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Technology
Table 34. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Molecular Diagnostics
Table 35. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Polymerase Chain Reactions (PCR)
Table 36. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Prescription Testing
Table 37. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sample
Table 38. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 39. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Hospitals And Clinics
Table 40. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Distribution Channel
Table 41. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Diseases
Table 42. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sexually Transmitted Diseases Testing
Table 43. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Tropical Diseases Testing
Table 44. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Technology
Table 45. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Molecular Diagnostics
Table 46. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Polymerase Chain Reactions (PCR)
Table 47. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Prescription Testing
Table 48. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Sample
Table 49. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 50. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Hospitals And Clinics
Table 51. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million) – by Distribution Channel
Table 52. Recent Organic Growth Strategies in North America Point-Of-Care Molecular Testing for Infectious Diseases Market
Table 53. Recent Inorganic Growth Strategies in the North America Point-Of-Care Molecular Testing For Infectious Diseases Market
Table 54. Glossary of Terms, Infectious Disease Diagnostics Market
1.1.2 List of Figures
Figure 1. North America Point-of-Care Molecular Testing for Infectious Diseases Market Segmentation, by Country
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue (US$ Million), 2021–2031
Figure 5. Pre and Post COVID-19 Impact
Figure 6. Patents filed by Top Companies for POC
Figure 7. Number of Patent Families for POC
Figure 8. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) – by Diseases, 2023 and 2031
Figure 9. HIV Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 10. Influenza Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 11. Sexually Transmitted Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 12. Hepatitis C Virus Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 13. Tropical Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 14. Respiratory Infection Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 15. Hospital Acquired Infections: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 16. Strep: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 17. Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 18. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) – by Technology, 2023 and 2031
Figure 19. Lateral Flow Assay: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 20. Dipsticks: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 21. Microfluidics: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 22. Molecular Diagnostics: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 23. Immunoassays: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 24. Solid Phase: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 25. Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 26. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) – by Prescription Testing, 2023 and 2031
Figure 27. Prescription Based Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 28. OTC Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 29. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) – by Sample, 2023 and 2031
Figure 30. Blood Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 31. Urine Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 32. Nasal and Oropharyngeal Swabs Sample: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 33. Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 34. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) – by End User, 2023 and 2031
Figure 35. Hospitals and Clinics: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 36. Home Care Settings: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 37. Ambulatory and Urgent Care Facilities: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 38. Nursing Home and Assisted Living Facilities: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 39. Research Laboratories: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 40. Diagnostics Centers: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 41. North America Point-of-Care Molecular Testing for Infectious Diseases Market Share (%) – by Distribution Channel, 2023 and 2031
Figure 42. E-Com Platforms: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 43. Retail Channel and Pharmacies: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 44. Others: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 45. North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown by Key Countries, 2023 and 2031 (%)
Figure 46. United States: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 47. Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 48. Mexico: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Million)
Figure 49. Growth Strategies in North America Point-Of-Care Molecular Testing for Infectious Diseases Market
The List of Companies - North America Point-of-Care Molecular Testing for Infectious Diseases Market
- Abbott Laboratories
- Agilent Technologies Inc
- Becton Dickinson and Co
- Bio-Rad Laboratories Inc
- Cardinal Health Inc,
- Danaher Corp
- Cue Health Inc,
- QuidelOrtho Corp
- Thermo Fisher Scientific Inc
- F. Hoffmann-La Roche Ltd.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to North America Point-of-Care Molecular Testing for Infectious Diseases Market
May 2024
Ovo-Sexing Technology Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Technique (Non-Invasive Imaging, Genetic Editing, Volatile Analysis, Sex Reversal, and Liquid-Based Analysis), End User (Hatcheries and Poultry Farms), and Geography (US, Germany, France, Italy, Spain, Rest of Europe, Israel, and ROW)
May 2024
Dental Laser Treatment Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Application (Hard Tissue, Soft Tissue, and Others), End User (Hospitals, Dental Clinics, Dental-Owned Practices, and Others), Clinical Indication [Conservative Dentistry, Root Canal (Endodontic Treatment), Oral Surgery, Implantology, Peri-Implantitis, Periodontics, and Others], and Geography
May 2024
Microbiology CRO Services Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Application (Clinical, Medical Device, and Others), Service Type (Assay Development, Custom Viral Stock Production, Microbial Testing, and Others), Microorganisms (Bacteria, Fungi, Viruses, and Parasites), End User (Biotech and Pharmaceutical Companies, Medical Device Companies, and Others), and Geography
May 2024
Electronic Patient-Reported Outcomes (ePROS) Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Delivery Mode (Cloud Based and On-Premises), Application (Oncology, Respiratory, and Others), End User [Contract Research Organizations (CROs), Pharmaceutical Companies, and Others], and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
May 2024
Antimicrobial Surgical Suture Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Triclosan Antimicrobial Suture and Chlorhexidine Antimicrobial Suture), Raw Materials (Polyglactin 910 Antimicrobial Suture, Poliglecaprone 25, and Polyglycolic Acid), Application (Cardiovascular Surgery, General Surgery, Ophthalmic Surgery, Gynecological Surgery, Orthopedic Surgery, Plastic Surgery, Veterinary Surgery, Dental Surgery, and Others), End User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
May 2024
Organoids Services Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Intestine, Liver, Stomach, Pancreas, Lung, Brain, Kidney, and Others), Application (Developmental Biology Disease, Pathology of Infectious Disease, Regenerative Medicine, Drug Toxicity & Efficacy Testing, Drug Discovery & Personalized Medicine, and Others), Source (Pluripotent Stem Cells and Organ Specific Adult Stem Cell), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
May 2024
Wellbeing Platform Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Service (Health Risk Assessment, Fitness, Smoking Cessation, Health Screening, Nutrition & Weight Management, Stress Management, Comprehensive Wellbeing, and Others), Category (Fitness & Nutrition Consultant, Psychological Therapists, and Organization/Employers), Delivery Model (Onsite and Offsite), End User (Small-Scale Organizations, Medium-Scale Organizations, Large-Scale Organization, and Homecare), and Geography
May 2024
Smart Hospital Beds Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Patient Weight (Less than 70 lb, 70 to 150 lb, 150 to 400 lb, 400 to 500 lb, Greater than 500 lb); Offering (Products and Accessories, Software and Solutions, and Services); Application (Fall Prevention, Pressure Injury Prevention, Patient Deterioration and Monitoring, and Others); End User (Hospitals, Clinics and Nursing Homes, Ambulatory Surgical Centers, Medical Laboratories, Long Term Care Centers, and Others), and Geography
Get Free Sample For